Sermorelin 10mg
Studied for growth-axis and performance research.
Sermorelin is a truncated GHRH (1-29) analog, one of the shortest GHRH fragments that retains full biological activity. It is studied as a "natural" GH-axis research tool — driving endogenous GH release via the GHRH receptor.
Proposed mechanism
Sermorelin binds the GHRH receptor in the anterior pituitary, stimulating endogenous growth-hormone release. Its short sequence (29 residues) is the minimal GHRH fragment that preserves receptor activity.
Research highlights
- GHRH (1-29) — the minimal active GHRH fragment
- Stimulates endogenous GH release
- Shorter half-life than tesamorelin or CJC-1295
- Long history in GH-axis research
Research protocol notes
Reconstitute under sterile technique with bacteriostatic water. Typical volumes range from 1–3 mL depending on the target working concentration. Swirl gently — do not shake — to avoid peptide shearing.
Stacking and comparative studies
Sometimes combined with ghrelin agonists (ipamorelin) for dual-pathway GH research.
Handling and storage
Lyophilized powder is stable at ambient shipping temperatures. Once reconstituted with bacteriostatic water, store at 2–8 °C and use within 28 days. For long-term storage of unreconstituted vials, freeze at −20 °C and protect from light.
Frequently asked
How does sermorelin compare to tesamorelin?
Tesamorelin is a stabilized GHRH (1-44) analog with better half-life. Sermorelin is the shorter GHRH (1-29) fragment — simpler structure but less protease-resistant.
How does it compare to CJC-1295?
CJC-1295 is GHRH (1-29) with additional stabilizing modifications (plus DAC in the longer-acting version). Sermorelin is the unmodified baseline.
Why short half-life?
Sermorelin lacks the protease-resistance modifications present in tesamorelin and CJC-1295. Half-life is measured in minutes rather than hours.
Is it still used in research?
Yes — its short action profile is desirable in some research designs precisely because it mimics native GHRH pulsatility.
